NAMSA Acquires Syntactx CRO Development Solutions

January 5, 2021—NAMSA, a medical device–focused contract research organization (CRO) providing full continuum development solutions, announced the acquisition of the CRO, Syntactx. In September 2020, independent health care investment firm ArchiMed made a majority interest purchase of NAMSA.

Syntactx, which was founded in 2010, synthesizes clinical evidence for global medtech sponsors to enable broad market adoption and commercial success of innovative medical products.

According to the NAMSA, Syntactx has enrolled more than 200,000 trial patients within the last 10 years. The company possesses significant expertise in complex interventional medical device trials and a deep-rooted understanding of enrollment obstacles and regulatory challenges and obligations.

NAMSA provides testing services to sponsors, in addition to quality, reimbursement, clinical research, and regulatory solutions. The CRO’s end-to-end development services are shown to help sponsors successfully address varying global requirements, including recently expanded criteria for medical device research and conduct (eg, medical device regulation and in vitro diagnostic regulation), resulting in increased regulatory oversight and clinical evidence requirements.

“This is a very exciting day for NAMSA, and I couldn’t be more pleased that Syntactx is joining the NAMSA family,” stated NAMSA President and CEO John Gorski in the company’s announcement. “Not only are our values and cultures well-aligned, but both organizations have a strong commitment to enhancing patient health care by safely and judiciously helping clients deliver innovative, life-changing medical devices to the global marketplace.”

Most notably, the company stated, NAMSA’s acquisition of Syntactx will enhance the company’s cardiovascular-focused regulatory consulting and clinical research solutions, while expanding electronic data capture, core lab imaging, safety, and physician consulting service offerings. These areas are key to further strengthening NAMSA’s history of assisting sponsors to proactively tackle development challenges head-on, achieve commercialization success, and positively impact patient lives.

Kenneth Ouriel, MD, President and CEO of Syntactx, added, “Syntactx is very proud to join NAMSA, a long-recognized industry leader in CRO medical device development and clinical research services. Syntactx’s corporate goals are wholly aligned with those of NAMSA. Relying on the latest technologies, a client-focused approach, and leveraging long-standing, trusted relationships with regulatory agencies and investigational sites, together, we will provide a range of services and level of quality unsurpassed in the global CRO industry.”